Search Results
Nov 18, 2025, 07:00 ET First Mining Announces Updated Pre-Feasibility Study for the Springpole Gold Project, Ontario, Canada
to announce the positive results of an updated Pre-Feasibility Study ("2025PFS") completed for its 100%-owned Springpole Gold Project (the "Project" or "Springpole") located in Ontario, Canada. The 2025 PFS results support a 30,000 tonnes-per-day ("tpd") open pit mining
More news about: First Mining Gold Corp.
Nov 17, 2025, 22:03 ET Mayfair Gold Q3 2025 Financial and Operating Results
gold project through permitting, detailed engineering and community engagement. The company continued to advance work on the Pre-Feasibility Study ("PFS") for a 4,800 tpd open pit operation targeting the high-grade near surface zone of mineralization at Fenn-Gib. The Company
More news about: Mayfair Gold Corp.
Nov 17, 2025, 06:30 ET Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
randomized 1:1 to receive neladalkib or ALECENSA® (alectinib). The primary endpoint is progression free survival (PFS) based on Blinded Independent Central Review (BICR). Secondary endpoints include PFS based on investigator's assessment, and BICR assessment of objective response rate (ORR), intracranial objective
More news about: Nuvalent, Inc.
Nov 17, 2025, 06:00 ET Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first OS interim
More news about: Jazz Pharmaceuticals plc
Nov 17, 2025, 06:00 ET Thesis Gold Continues to Derisk Lawyers-Ranch Through Drilling
of British Columbia. This year's work focused on geotechnical, hydrological, and metallurgical studies to support the ongoing Prefeasibility Study ("PFS") and to advance the technical work required for future feasibility-level designs, reflecting the Company's continued commitment to de-risking the Project.
More news about: Thesis Gold Inc.
Nov 17, 2025, 04:00 ET Denison Announces Agreements with Skyharbour Resources, Increasing Denison's Strategic Foothold Surrounding Wheeler River
feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Nov 13, 2025, 14:19 ET AICPA Holiday Spending Survey Reveals Budgeting, Debt and a Bit of Regret
"The 2025 holiday season could see many Americans balancing the desire to celebrate with the reality of financial strain," says Dan Snyder, CPA/PFS, Director of AICPA Personal Financial Planning. "Economic uncertainty may lead Americans to cut back on holiday spending and nearly half of those who
More news about: AICPA
Nov 13, 2025, 08:59 ET Stroudwater Associates Releases the 2025 Rural Provider Compensation Report
the current CMS physician fee schedule for determining wRVUs, and over half the organizations surveyed did not know which CMS physician fee schedule (PFS) they were using.63.6% of the organizations surveyed were using the 2023 CMS physician fee schedule.
More news about: Stroudwater Associates
Nov 12, 2025, 17:08 ET i-80 Gold Reports Third Quarter 2025 Results and Project Development Progress
underground (FS) — Q1 2026 Granite Creek open pit (PFS/FS) — Timeline under review Archimedes underground (FS) — Q1 2027 Mineral Point open pit (PFS/FS) — Timeline under review
More news about: i-80 Gold Corp
Nov 12, 2025, 13:00 ET Year-End Tax and Financial Planning Tips from CPAs
next. "Taking action before the end of this year can be a huge benefit to your financial health in 2026," says Dan Snyder, CPA/PFS, Director of AICPA Personal Financial Planning. "There have been many changes in the tax and financial planning space this year and now is the time
More news about: AICPA
Nov 12, 2025, 08:00 ET Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
demonstrated a statistically significant benefit on overall response rate (ORR) and progression-free survival (PFS) in patients with high levels of DKK1, along with a positive trend on ORR and PFS in the full intent-to-treat population. Across the
More news about: Cypherpunk Technologies Inc.
Nov 12, 2025, 08:00 ET Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
demonstrated a statistically significant benefit on overall response rate (ORR) and progression-free survival (PFS) in patients with high levels of DKK1, along with a positive trend on ORR and PFS in the full intent-to-treat population. Across the
More news about: Cypherpunk Technologies Inc.
Nov 12, 2025, 07:00 ET Grounded Lithium Reports Third Quarter 2025 Financial Results and Project Update
Denison Mines Corp ("Denison"), continues to progress the various technical studies necessary for the completion of the pre-feasibility study ("PFS"). Areas of focus include extensive engineering analysis in cost minimization for lithium extraction from the brine to produce a final lithium hydroxide
More news about: Grounded Lithium Corp.
Nov 11, 2025, 08:58 ET iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
patients). When analyzed by PD-L1 status, ORR was 87% in PD-L1–positive patients and 60% in PD-L1–negative patients. Median progression-free survival (PFS) has not yet been reached and is projected to exceed 12 months. In the post–immunotherapy (post-IO) NSCLC cohort (n=3), ILKN421H combined with pembrolizumab
More news about: iLeukon Therapeutics
Nov 10, 2025, 07:30 ET ADC Therapeutics Reports Third Quarter 2025 Financial Results and Provides Operational Update
with an overall response rate (ORR) of 98.2%, a complete response rate (CR) of 83.6%. After median follow-up of 28 months, median PFS was not reached, and the 12-month PFS was 93.9%. Safety was consistent with the known profile of ZYNLONTA. The trial has been expanded to enroll 100 patients, and the Company
More news about: ADC Therapeutics SA
Nov 10, 2025, 07:00 ET MAYFAIR PROVIDES FENN-GIB PROJECT UPDATE
Geotechnical Site Investigations for the tailing storage facility and a progress update on the Pre-Feasibility Study ("PFS") work. The Company's upcoming PFS will be based on the recently updated NI 43-101 Mineral Resource Estimate ("MRE") for the Fenn-Gib Project (see
More news about: Mayfair Gold Corp.
Nov 09, 2025, 20:55 ET Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
5 mg/kg groups. Median duration of response (DOR) was 9.3 months and 8.7 months in the 4 mg/kg and 5 mg/kg groups. Median progression free survival (PFS) was 6.0 months and 7.3 months in the 4 mg/kg and 5 mg/kg groups. Grade ≥3 treatment-related AEs (TRAEs) occurred in 59 patients
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 07, 2025, 11:30 ET Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74
statistically significant benefits in both Progression-Free Survival (PFS) and Overall Survival (OS). This final OS analysis, the first from a Phase III trial of ivonescimab, confirms the breakthrough value of ivonescimab-based therapy in improving both PFS and OS. Historically, cancer immunotherapies have largely
More news about: Akeso, Inc.
Nov 06, 2025, 20:00 ET Denison Reports Financial and Operational Results for Q3 2025, Including First Production from McClean North Uranium Mine
feasibility study was completed for the Phoenix deposit as an ISR mining operation, and an update to the previously prepared 2018 Pre-Feasibility Study ('PFS') was completed for Wheeler River's Gryphon deposit as a conventional underground mining operation. Based on the respective studies, both deposits have
More news about: Denison Mines Corp.
Nov 06, 2025, 18:44 ET Wheaton Precious Metals Announces Record Revenue, Earnings and Cash Flow for the First Nine Months of 2025
as a large-scale, long-life open pit gold project with robust economics. Based on the results of the PEA, Aris has initiated a Prefeasibility Study ("PFS"), targeted for completion in 2026, with the objective of advancing the project toward construction.
More news about: Wheaton Precious Metals Corp.
Nov 06, 2025, 17:07 ET DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
progression-free survival (PFS), defined as progression to active multiple myeloma (MM) as assessed by an independent review committee, according to IMWG diagnostic criteria for MM (SLiM-CRAB), or death. Major secondary endpoints included overall response rate, PFS on first-line MM treatment (PFS2), and overall survival.
More news about: Johnson & Johnson
Nov 06, 2025, 08:00 ET OncoHost Wins 'Proteomics Innovation of the Year' at the BioTech Breakthrough Awards
of proteins are profiled and analyzed with proprietary AI models, generating patient-specific predictive scores for both progression-free survival (PFS) and overall survival (OS). The PROphet® proteomic signature has also demonstrated predictive value across melanoma, renal cell carcinoma (RCC), HPV-associated
More news about: OncoHost
Nov 06, 2025, 07:00 ET Mark Cuban Cost Plus Drug Company Expands Access with Addition of Starjemza® (ustekinumab-hmny) to Give Patients More Power Over Prescription Costs
Starjemza® will be listed at a starting price of $345 per quarter (plus shipping) for the 90 mg/mL pre-filled syringe (PFS). Additional configurations, including the 45 mg/mL and 130 mg/mL PFS, will also be offered and priced in accordance with the company's transparent cost-plus model.
More news about: Mark Cuban Cost Plus Drug Company
Nov 05, 2025, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
ES-SCLC based on positive data from the Phase 3 IMforte trial. Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25; updated intent-to-treat population for PFS to include all patients enrolled in the trial. Narrowed 2025 total revenue
More news about: Jazz Pharmaceuticals plc
Nov 05, 2025, 16:05 ET Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
ES-SCLC based on positive data from the Phase 3 IMforte trial. Top-line PFS data from zanidatamab in Phase 3 1L GEA expected in 4Q25; updated intent-to-treat population for PFS to include all patients enrolled in the trial. Narrowed 2025 total revenue
More news about: Jazz Pharmaceuticals plc